Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis
NCT ID: NCT00036153
Last Updated: 2012-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
210 participants
INTERVENTIONAL
2002-03-31
2004-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy
NCT00106522
The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment
NCT02837978
A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate
NCT01224418
Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis
NCT01749787
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
NCT01661140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tacrolimus (Prograf®)
Methotrexate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a diagnosis of Rheumatoid Arthritis using American College of Rheumatology Criteria, of at least 6 months duration
* Have been receiving oral or parenteral methotrexate for at least 3 months
Exclusion Criteria
* Has moderate or severe liver disease
* Has a known history of HIV infection
* Has serum creatinine outside the normal range
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma US, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Rheumatology Associates of North Alabama
Huntsville, Alabama, United States
Radiant Research, Pharmaceutical Clinical Trials Division
Scottsdale, Arizona, United States
Boling Clinical Trials
Rancho Cucamonga, California, United States
San Diego Arthritis & Osteoporosis Medical Clinic
San Diego, California, United States
Pacific Arthritis Center and Medical Group
Santa Maria, California, United States
Arthritis Associates of CT
Danbury, Connecticut, United States
Stamford Therapeutic Consortium
Stamford, Connecticut, United States
Center of Rheumatology, Immunology & Arthritis
Fort Lauderdale, Florida, United States
Arthritis Center
Palm Harbor, Florida, United States
Sarasota Arthritis Center, Rheumatology Division
Sarasota, Florida, United States
Arthritis & Rheumatology Associates of Palm Beach
West Palm Beach, Florida, United States
Coeur d'Alene Arthritis Clinic
Coeur d'Alene, Idaho, United States
Northwestern Center for Clinical Research
Chicago, Illinois, United States
Decatur Memorial Hospital
Decatur, Illinois, United States
Illinois Bone & Joint Institute
Morton Grove, Illinois, United States
Rockford Clinical
Rockford, Illinois, United States
The Arthritis Center
Springfield, Illinois, United States
Arthritis & Osteoporosis Center of Maryland
Frederick, Maryland, United States
Phase III Clinical Research
Fall River, Massachusetts, United States
Midwest Arthritis Center
Kalamazoo, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
St. Louis Center for Clinical Research
St Louis, Missouri, United States
Arthritis Consultants
St Louis, Missouri, United States
Arthritis Regional Research Center
Mercerville, New Jersey, United States
New Jersey Physicians, LLC
Passaic, New Jersey, United States
North Carolina Arthritis & Allergy Care Center
Raleigh, North Carolina, United States
Radiant Research - Columbus
Columbus, Ohio, United States
STAT Research, Inc.
Dayton, Ohio, United States
PRO Research
Eugene, Oregon, United States
Oregon Health Sciences Center
Portland, Oregon, United States
Portland Medical Associates, P.C.
Portland, Oregon, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Center for Assessment & Research of Erie
Erie, Pennsylvania, United States
Central Pennsylvania Clinical Research
Mechanicsburg, Pennsylvania, United States
Clinical Research Center of Reading, LLP
West Reading, Pennsylvania, United States
Rheumatic Disease Associates
Willow Grove, Pennsylvania, United States
Radiant Research - Dallas
Dallas, Texas, United States
San Antonio Center for Clinical Research
San Antonio, Texas, United States
Physicians Research Options, L.C.
Sandy City, Utah, United States
Metropolitan Clinical Research
Falls Church, Virginia, United States
Lewis-Gale Clinic
Salem, Virginia, United States
Doctor's Office
Hamilton, Ontario, Canada
Doctor's Office
Hamilton, Ontario, Canada
The Arthritis Program Research Group, Inc.
Newmarket, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01-0-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.